A Phase 2 interventional study of VS-01 on top of SOC and SOC (Control Group) in Acute-On-Chronic Liver Failure and Ascites, sponsored by Genfit. Terminated at 26 sites in 7 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Genfit · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver cirrhosis (Acute-on-Chronic Liver Failure, ACLF) and accumulation of fluid in the abdominal cavity (ascites)
167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.
This study's enrollment of 15 is below the median of 73 across 96 interventional studies indexed under Acute-On-Chronic Liver Failure.
Browse Acute-On-Chronic Liver Failure studies →Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence of any of the following organ failure(s) as per the EASL-CLIF criteria and/or adapted from CLIF-C Organ Failure (CLIF-C OF)/CLIF- Sequential Organ Failure Assessment (CLIF-SOFA) scores:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to Active Treatment group will receive VS-01 on top of SOC
Drug: VS-01 on top of SOC
Patients randomized to Control group will receive SOC defined as the standard medical management of patients with decompensated cirrhosis and ACLF
Other: SOC (Control Group)
Patients will receive VS-01 intraperitoneally on four consecutive days on top of SOC
Patients will receive SOC for decompensated cirrhosis and ACLF
Chronic Liver Failure Consortium (CLIF-C) ACLF Score at Day 7
The CLIF-C ACLF score is derived from the CLIF-C organ failure (OF) score. The formula for the CLIF-C ACLF score is CLIF-ACLF = 10\*\[0.33\*CLIF-C OF + 0.04\*Age + 0.63\*Ln(white cell count) -2\]. The CLIF-C ACLF score ranges from 0-100, where a higher score indicated a greater mortality risk.
Time frame: Day 7
Number of Deaths From Day 1 to Day 90
90-Day mortality was reported as the number of deaths from Day 1 to Day 90.
Time frame: Day 1 to Day 90
Number of Deaths From Day 1 to Day 28
28-Day mortality was reported as the number of deaths from Day 1 to Day 28.
Time frame: Day 1 to Day 28
Time to Death Through Day 90
Time to death was calculated as death date - treatment start date. Participants who were not observed to have encountered the event through Day 90 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.
Time frame: Day 1 to Day 90
Number of Participants With ACLF Resolution
ACLF resolution was defined as ACLF grade 'No ACLF', for participants who had ACLF at Baseline.
Time frame: Baseline to Day 7 and Day 28
Time to ACLF Resolution Through Day 28
ACLF resolution was defined as ACLF grade 'No ACLF', for participants who had ACLF at Baseline. Time to ACLF resolution was calculated as (ACLF resolution date - treatment start date). Participants who were not observed to have encountered the event through Day 28 were censored at min\[trial discontinuation date; Day 28 visit date or treatment start date +27 if no visit date; last contact/assessment date for participant lost to follow-up; date of liver transplant or transjugular intrahepatic portosystemic shunt (TIPS)\]. The inter-quartile range was obtained via Kaplan Meier estimation.
Time frame: Baseline to Day 28
Number of Participants With ≥ 1 ACLF Grade Regression
ACLF regression was defined as regression of at least one full grade.
Time frame: Baseline, Day 7 and Day 28
Time to ≥ 1 ACLF Grade Regression Through Day 28
Time to ACLF ≥ 1 grade regression was calculated as (ACLF ≥ 1 grade regression date - treatment start date). Participants who were not observed to have encountered the event through Day 28 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.
Time frame: Baseline and Day 28
Secondary: Time to Transplant or Death Through Day 90
Time to transplant was calculated as (transplant or death date - treatment start date). Participants who were not observed to have encountered the event through Day 90 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.
Time frame: Day 1 through Day 90
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a study drug and that does not necessarily have a causal relationship with this treatment. A TEAE was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after at least one dose of the study drug had been administered, even if the event was not considered to be related to the study drug. A serious AE (SAE) was any untoward medical event that occurs at any dose that: resulted in death; was life-threatening; required in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; or was an important medical event.
Time frame: Up to Day 90
A total of 15 participants were enrolled into this trial in the United States, Germany and France between July 2023 and October 2025.
| Milestone | Active Treatment Group: VS-01 on Top of Standard of Care (SOC) | Control Group: SOC Alone |
|---|---|---|
| Started | 9 | 6 |
| Completed | 3 | 2 |
| Not completed | 6 | 4 |
| Withdrew: Death | 4 | 2 |
| Withdrew: Liver transplant | 2 | 0 |
| Withdrew: Withdrawal of consent | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
The CLIF-C ACLF score is derived from the CLIF-C organ failure (OF) score. The formula for the CLIF-C ACLF score is CLIF-ACLF = 10\*\[0.33\*CLIF-C OF + 0.04\*Age + 0.63\*Ln(white cell count) -2\]. The CLIF-C ACLF score ranges from 0-100, where a higher score indicated a greater mortality risk.
| score on a scale | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Chronic Liver Failure Consortium (CLIF-C) ACLF Score at Day 7 | 50.852 ± 15.5459 | 39.866 ± 6.3557 |
90-Day mortality was reported as the number of deaths from Day 1 to Day 90.
| Participants | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Number of Deaths From Day 1 to Day 90 | 4 | 1 |
28-Day mortality was reported as the number of deaths from Day 1 to Day 28.
| Participants | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Number of Deaths From Day 1 to Day 28 | 4 | 0 |
Time to death was calculated as death date - treatment start date. Participants who were not observed to have encountered the event through Day 90 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.
| days | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Time to Death Through Day 90 | NA (18 to —) | NA |
ACLF resolution was defined as ACLF grade 'No ACLF', for participants who had ACLF at Baseline.
| Participants | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Day 7 — Resolution | 1 | 1 |
| Day 7 — No Resolution | 2 | 2 |
| Day 28 — Resolution | 1 | 2 |
| Day 28 — No Resolution | 2 | 1 |
ACLF resolution was defined as ACLF grade 'No ACLF', for participants who had ACLF at Baseline. Time to ACLF resolution was calculated as (ACLF resolution date - treatment start date). Participants who were not observed to have encountered the event through Day 28 were censored at min\[trial discontinuation date; Day 28 visit date or treatment start date +27 if no visit date; last contact/assessment date for participant lost to follow-up; date of liver transplant or transjugular intrahepatic portosystemic shunt (TIPS)\]. The inter-quartile range was obtained via Kaplan Meier estimation.
| days | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Time to ACLF Resolution Through Day 28 | NA (3 to —) | 13 (5 to —) |
ACLF regression was defined as regression of at least one full grade.
| Participants | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Day 7 — Regression | 1 | 1 |
| Day 7 — No Regression | 8 | 5 |
| Day 28 — Regression | 1 | 2 |
| Day 28 — No Regression | 8 | 4 |
Time to ACLF ≥ 1 grade regression was calculated as (ACLF ≥ 1 grade regression date - treatment start date). Participants who were not observed to have encountered the event through Day 28 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.
| days | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Time to ≥ 1 ACLF Grade Regression Through Day 28 | NA | NA (13 to —) |
Time to transplant was calculated as (transplant or death date - treatment start date). Participants who were not observed to have encountered the event through Day 90 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.
| days | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Death | 22 (18 to —) | NA |
An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a study drug and that does not necessarily have a causal relationship with this treatment. A TEAE was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after at least one dose of the study drug had been administered, even if the event was not considered to be related to the study drug. A serious AE (SAE) was any untoward medical event that occurs at any dose that: resulted in death; was life-threatening; required in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; or was an important medical event.
| Participants | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Any TEAEs | 9 | 6 |
| Any Grade 3 or Higher TEAEs | 8 | 5 |
| Any TEAEs Related to VS-01 | 6 | NA |
| Any Serious TEAEs | 7 | 5 |
| Any Serious TEAEs Related to VS-01 | 2 | NA |
Collected over Up to Day 90. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Treatment Group: VS-01 on Top of SOC | 4/9 (44.4%) | 7/9 (77.8%) | 9/9 (100%) |
| Control Group: SOC Alone | 2/6 (33.3%) | 5/6 (83.3%) | 6/6 (100%) |
| Event | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| Hepatic encephalopathyNervous system disorders | 2/9 | 0/6 |
| Chronic hepatic failureHepatobiliary disorders | 1/9 | 1/6 |
| Hepatic cirrhosisHepatobiliary disorders | 1/9 | 1/6 |
| PneumoniaInfections and infestations | 0/9 | 1/6 |
| Disturbance in attentionNervous system disorders | 0/9 | 1/6 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/9 | 1/6 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/9 | 1/6 |
| HyponatraemiaMetabolism and nutrition disorders | 0/9 | 1/6 |
| Mental status changesPsychiatric disorders | 0/9 | 1/6 |
| Acute on chronic liver failureHepatobiliary disorders | 1/9 | 0/6 |
| Event | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone |
|---|---|---|
| HypocalcaemiaMetabolism and nutrition disorders | 3/9 | 0/6 |
| HypokalaemiaMetabolism and nutrition disorders | 1/9 | 2/6 |
| DiarrhoeaGastrointestinal disorders | 2/9 | 2/6 |
| AnaemiaBlood and lymphatic system disorders | 1/9 | 2/6 |
| HyperkalaemiaMetabolism and nutrition disorders | 2/9 | 0/6 |
| HypomagnesaemiaMetabolism and nutrition disorders | 2/9 | 0/6 |
| PneumoniaInfections and infestations | 2/9 | 1/6 |
| EncephalopathyNervous system disorders | 2/9 | 0/6 |
| SyncopeNervous system disorders | 2/9 | 0/6 |
| Acute kidney injuryRenal and urinary disorders | 2/9 | 0/6 |
Full Analysis Set (FAS): All randomized participants.
| Age, Continuous(years) | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone | Total |
|---|---|---|---|
| Mean | 56.59 ± 8.210 | 51.18 ± 11.295 | 54.43 ± 9.571 |
| Sex: Female, Male(Participants) | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone | Total |
|---|---|---|---|
| Female | 0 | 3 | 3 |
| Male | 9 | 3 | 12 |
| Race (NIH/OMB)(Participants) | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 6 | 5 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Active Treatment Group: VS-01 on Top of SOC | Control Group: SOC Alone | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 6 | 6 | 12 |
| Unknown or Not Reported | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Oct 2025, 27 months.
Results were first posted in Jul 2026, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acute-On-Chronic Liver Failure →